echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > CanSino disclosed the results of a recent sequential strengthening clinical study of the new crown mRNA epidemic

    CanSino disclosed the results of a recent sequential strengthening clinical study of the new crown mRNA epidemic

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    The novel coronavirus mRNA epidemic seedling CS-2034 (hereinafter referred to as "CS-2034"), jointly developed by CanSino Biologics Co.
    , Ltd.
    (hereinafter referred to as the "Company") and its subsidiary CanSino (Shanghai) Biotechnology Co.
    , Ltd.
    , has obtained positive phased data
    in a clinical study evaluating sequential enhancement safety and immunogenicity.

    CS-2034 is a protective mRNA vaccine of existing variants, and preclinical studies have shown that this vaccine can induce high-titer neutralizing antibodies against multiple WHO-recognized important variants, which is more broad-spectrum than the new coronavirus seedlings developed based on prototype strains, and can more effectively protect the body from infection by existing variants

    Up to now, CS-2034 is still in the clinical phase IIb stage, and the current progress is in line with expectations, and the next stage of R&D will be planned
    in the future according to the epidemic situation, national immunization strategy, review mechanism, etc.
    , and based on the positive clinical data obtained.

    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.